IVD Raw Material Market

研究執行與發布：MarketsandMarkets　·　發布日期 2026-08-14　·　500 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

完整報告名稱與涵蓋範圍

IVD Raw Material Market by Product Type (Proteins, Beads, Particles, Antibodies), Technology (Immunoassay, Hematology), Application (Infectious Disease, Diabetes), Supply Source, Origin (Biological, Synthetic), End User (CROs) - Global Forecast to 2031

報告摘要

The IVD raw material market is projected to grow from USD 21.5 billion in 2026 to USD 31.1 billion by 2031, growing at a CAGR of 7.7%. The increasing prevalence of chronic and infectious diseases, the rising demand for early and accurate disease diagnosis, and the expanding adoption of advanced diagnostic technologies. The growing use of molecular diagnostic techniques such as PCR, NGS, FISH, and LAMP is increasing demand for high-quality oligonucleotides, nucleic acids, enzymes, and other specialized raw materials. At the same time, the rapid expansion of point-of-care testing is driving the need for antibodies, antigens, membranes, labels, and detection materials used in rapid diagnostic assays. Furthermore, advancements in recombinant technologies, protein engineering, and assay development are improving the performance, sensitivity, and reliability of diagnostic tests. These innovations are enabling diagnostic manufacturers to develop more accurate and efficient testing solutions, thereby supporting the growth of the global IVD raw material market. “The infectious disease testing segment is expected to account for the largest share of the IVD raw material market, by application, during the forecast period.” Based on application, the IVD raw material market is segmented into infectious disease testing, oncology/cancer markers, cardiac markers, diabetes & metabolic disorders, autoimmune disease, blood screening, women's health & fertility, genetic & rare disease testing, and others. The infectious disease testing segment accounts for the largest market share due to the high global burden of infectious diseases and the increasing demand for rapid, accurate, and large-scale diagnostic testing. Diagnostic manufacturers extensively use raw materials such as antibodies, antigens, enzymes, oligonucleotides, nucleic acids, and detection reagents to develop immunoassays, molecular diagnostic tests, and point-of-care testing solutions for detecting bacterial, viral, fungal, and parasitic infections. Additionally, growing investments in public health programs, increasing awareness of early disease diagnosis, and the continued adoption of advanced molecular diagnostic technologies are driving demand for high-quality IVD raw materials in infectious disease testing, making it the largest application segment of the market. “The immunoassay segment has the largest market share in the IVD raw material market during the forecast period.” The global IVD raw material market can be segmented by technology into immunoassay, molecular diagnostics, clinical chemistry, hematology, microbiology & culture, coagulation, point-of-care testing, flow cytometry, and others. Among these, the immunoassay segment accounted for the largest market share. Immunoassay-based diagnostics remain a fundamental component of routine disease testing due to their high sensitivity, specificity, cost-effectiveness, and broad application across infectious diseases, oncology, cardiac markers, autoimmune disorders, and hormone testing. The widespread adoption of immunoassay platforms has generated substantial demand for critical raw materials, including antibodies, antigens, proteins, enzymes, labels, and detection reagents. Furthermore, continuous advancements in assay development, increasing diagnostic testing volumes, growing demand for rapid and accurate diagnostic solutions, and the expansion of automated immunoassay analyzers are expected to support the continued adoption of immunoassay technologies, thereby driving demand for IVD raw materials worldwide. “Asia Pacific: The fastest-growing market for IVD raw material from 2026 to 2031” The global IVD raw material market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific is projected to grow at the highest regional CAGR from 2026 to 2031. The region's growth is driven by the increasing prevalence of chronic and infectious diseases, expanding healthcare infrastructure, rising investments in diagnostic technologies, and growing demand for early and accurate disease diagnosis. China is strengthening its domestic diagnostic manufacturing capabilities through healthcare modernization initiatives and increased investment in biotechnology and life sciences. India is witnessing significant growth in diagnostic testing volumes, supported by the expansion of clinical laboratories and molecular diagnostic facilities, as well as the adoption of point-of-care testing. Additionally, Japan's advanced healthcare system, aging population, and strong focus on precision medicine continue to drive demand for high-quality diagnostic assays and the raw materials required for their development. These factors are expected to support the rapid growth of the IVD raw material market across the Asia Pacific region during the forecast period. The break-up of the profile of primary participants in the IVD raw market: • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier - 30% • By Designation: C-level Executives - 27%, Directors – 18%, and Others - 55% • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa - 4% Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), Medix Biochemica (Finland), Bio-Techne Corporation (U.S.), Fapon Biotech Inc. (China), Meridian Bioscience, Inc. (U.S.), BBI Solutions (U.K.), Toyobo Co., Ltd. (Japan), Roche CustomBiotech (Switzerland), Integrated DNA Technologies, Inc. (U.S.), Cytiva (U.S.), Sartorius AG (Germany), LGC Biosearch Technologies (U.S.), Fitzgerald Industries International (U.S.), and Bangs Laboratories, Inc. (U.S.) are some of the key players operating in the global IVD raw material market. Research Coverage: This research report categorizes the IVD raw material market by product type (antibodies, antigens & proteins, enzymes & substrates, oligonucleotides & nucleic acids, beads & particles, membranes, labels & detection materials, buffers & diluents, and others), by technology (immunoassay, molecular diagnostics, clinical chemistry, hematology, microbiology & culture, coagulation, point-of-care testing, flow cytometry, and others), by application (infectious disease testing, oncology/cancer markers, cardiac markers, diabetes & metabolic disorders, autoimmune disease, blood screening, women's health & fertility, genetic & rare disease testing, and others), by supply source (in-house manufacturing [captive] and third-party supply [merchant]), by source/origin (biological/natural source, recombinant/synthetic, and others), by end user (IVD manufacturers, contract research organizations, academic & research institutes, pharmaceutical & biotech companies, and others), and by region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the IVD raw material market. A detailed analysis of the key industry players has been conducted to provide insights into their business overview, product portfolios, key strategies such as acquisitions, partnerships, collaborations, capacity expansions, and product launches, as well as recent developments associated with the IVD raw material market. Competitive analysis of emerging companies and market participants within the IVD raw materials ecosystem is also covered in this report. Reasons to buy this report: The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall IVD raw material market and the subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (increasing geriatric population and subsequent rise in chronic diseases, growing awareness of early disease diagnosis in emerging economies, emergence of rapid point-of-care [POC] technologies and rising adoption of automated analyzers, and growing preference for personalized medicine), restraints (unfavorable reimbursement scenario, stringent regulatory requirements), opportunities (introduction of disease-specific biomarkers and tests, increasing significance of companion diagnostics, growth opportunities in developing countries, improvements in immunoassay diagnostic technologies, and the growing digitalization trend), and challenges (maintaining batch-to-batch consistency and quality of raw materials, and supply chain disruptions affecting the availability of critical biological and synthetic reagents) influencing the growth of the IVD raw material market • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the IVD raw material market • Market Development: Comprehensive information about lucrative markets—the report analyzes the IVD raw material market across varied regions. • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the IVD raw material market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product portfolios of leading players such as Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), Medix Biochemica (Finland), Bio-Techne Corporation (U.S.), and Fapon Biotech Inc. (China), among others

授權報價

Single User Licence	$4,950 USD
Multi User Licence	$6,650 USD
Corporate User Licence	$8,150 USD
Global User Licence	$10,000 USD

目錄 Table of Contents

1 INTRODUCTION 41 1.1 STUDY OBJECTIVES 41 1.2 MARKET DEFINITION 41 1.3 STUDY SCOPE 42 1.3.1 MARKETS COVERED AND REGIONAL SCOPE 42 1.3.2 INCLUSIONS AND EXCLUSIONS 43 1.3.3 YEARS CONSIDERED 44 1.3.4 CURRENCY CONSIDERED 44 1.4 STAKEHOLDERS 44 2 EXECUTIVE SUMMARY 45 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 45 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 46 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 47 2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS 48 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 49 3 PREMIUM INSIGHTS 50 3.1 IVD RAW MATERIALS MARKET OVERVIEW 50 3.2 IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2026 VS. 2031 51 3.3 IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2026 VS. 2031 51 3.4 IVD RAW MATERIALS MARKET, BY APPLICATION, 2026 VS. 2031 52 3.5 IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2026 VS. 2031 52 3.6 IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2026 VS. 2031 53 3.7 IVD RAW MATERIALS MARKET, BY END USER, 2026 VS. 2031 53 3.8 IVD RAW MATERIALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 54 4 MARKET OVERVIEW 55 4.1 INTRODUCTION 55 4.2 MARKET DYNAMICS 55 4.2.1 DRIVERS 56 4.2.1.1 Rising prevalence of chronic and infectious diseases 56 4.2.1.2 Growing adoption of personalized medicine and companion diagnostics 56 4.2.1.3 Increasing use of recombinant antibodies, proteins, and enzymes 57 4.2.1.4 Growing demand for raw materials supporting decentralized and rapid diagnostics 58 4.2.2 RESTRAINTS 58 4.2.2.1 High validation and quality-control costs 58 4.2.2.2 Long supplier qualification cycles 59 4.2.2.3 Limited availability of specialized biological raw materials 59 4.2.3 OPPORTUNITIES 60 4.2.3.1 Adoption of recombinant and animal-free raw materials 60 4.2.3.2 Localization of raw material manufacturing in emerging markets 60 4.2.3.3 Development of next-generation molecular diagnostic reagents 61 4.2.4 CHALLENGES 62 4.2.4.1 Maintaining batch-to-batch consistency 62 4.2.4.2 Building resilient supply chains for critical biological inputs 62 4.2.4.3 Meeting evolving IVDR/FDA supplier documentation requirements 63 4.3 UNMET NEEDS AND WHITE SPACES 63 4.3.1 UNMET NEEDS IN IVD RAW MATERIALS MARKET 63 4.3.2 WHITE SPACE OPPORTUNITIES 64 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 65 4.4.1 INTERCONNECTED MARKETS 65 4.4.2 CROSS-SECTOR OPPORTUNITIES 65 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 66 4.5.1 KEY MOVES AND STRATEGIC FOCUS 66 5 INDUSTRY TRENDS 68 5.1 PORTER’S FIVE FORCES ANALYSIS 68 5.1.1 THREAT OF NEW ENTRANTS 69 5.1.2 THREAT OF SUBSTITUTES 69 5.1.3 BARGAINING POWER OF SUPPLIERS 69 5.1.4 BARGAINING POWER OF BUYERS 70 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 70 5.2 MACROECONOMIC INDICATORS 70 5.2.1 INTRODUCTION 70 5.2.2 GDP TRENDS AND FORECAST 70 5.3 SUPPLY CHAIN ANALYSIS 72 5.4 VALUE CHAIN ANALYSIS 73 5.5 ECOSYSTEM ANALYSIS 75 5.6 PRICING ANALYSIS 76 5.6.1 AVERAGE SELLING PRICE, BY REGION, 2024–2026 76 5.6.2 AVERAGE SELLING PRICE, BY KEY PLAYER, 2024–2026 77 5.7 TRADE ANALYSIS 78 5.7.1 IMPORT SCENARIO (HS CODE 300213) 78 5.7.2 EXPORT SCENARIO (HS CODE 300213) 78 5.8 KEY CONFERENCES & EVENTS, 2026–2027 79 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 79 5.10 INVESTMENT & FUNDING SCENARIO 80 5.11 IMPACT OF US TARIFFS—IVD RAW MATERIALS MARKET 81 5.11.1 INTRODUCTION 81 5.11.2 KEY TARIFF RATES 81 5.11.3 PRICE IMPACT ANALYSIS 82 5.11.4 IMPACT ON REGIONS 82 5.11.4.1 North America 82 5.11.4.2 Europe 82 5.11.4.3 Asia Pacific 83 5.11.5 IMPACT ON END-USE INDUSTRIES 83 5.11.5.1 OEM IVD manufacturers 83 5.11.5.2 Biopharmaceutical companies 83 5.11.5.3 CROs and research institutions 83 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 84 6.1 KEY EMERGING TECHNOLOGIES 84 6.1.1 IMMUNOASSAY 84 6.2 COMPLEMENTARY TECHNOLOGIES 84 6.2.1 MOLECULAR DIAGNOSTICS 84 6.3 TECHNOLOGY/PRODUCT ROADMAP 85 6.4 PATENT ANALYSIS 87 6.4.1 LIST OF KEY PATENTS 88 6.5 FUTURE APPLICATIONS 88 6.6 IMPACT OF AI/GENERATIVE AI ON IVD RAW MATERIALS MARKET 89 6.6.1 INTRODUCTION 89 6.6.2 TOP USE CASES AND MARKET POTENTIAL 90 6.6.3 KEY COMPANIES IMPLEMENTING AI 90 6.6.4 FUTURE OF AI 91 7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 92 7.1 REGIONAL REGULATIONS AND COMPLIANCE 92 7.1.1 REGULATORY LANDSCAPE 92 7.1.1.1 North America 92 7.1.1.1.1 US 92 7.1.1.1.2 Canada 93 7.1.1.2 Europe 94 7.1.1.3 Asia Pacific 94 7.1.1.3.1 Japan 95 7.1.1.3.2 China 95 7.1.1.3.3 India 96 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96 7.1.2.1 North America 97 7.1.2.2 Europe 97 7.1.2.3 Asia Pacific 97 7.1.2.4 Latin America 98 7.1.2.5 Middle East & Africa 98 7.2 SUSTAINABILITY INITIATIVES 98 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN IVD RAW MATERIALS MARKET 98 7.2.1.1 Eco-friendly Initiatives 99 7.2.2 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES 100 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 101 8.1 DECISION-MAKING PROCESS 101 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 101 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 101 8.2.2 BUYING CRITERIA 102 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 103 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 104 8.5 MARKET PROFITABILITY 104 8.5.1 REVENUE POTENTIAL 105 8.5.2 COST DYNAMICS 105 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 105 9 IVD RAW MATERIALS MARKET, BY PRODUCT TYPE 106 9.1 INTRODUCTION 107 9.2 ANTIBODIES 107 9.2.1 MONOCLONAL ANTIBODIES 110 9.2.1.1 Increasing demand for highly specific and reproducible antibody reagents in immunoassay and rapid diagnostic applications to drive segment growth 110 9.2.2 POLYCLONAL ANTIBODIES 112 9.2.2.1 Broad target recognition and strong signal generation to sustain demand for polyclonal antibodies in diagnostic assays 112 9.2.3 RECOMBINANT ANTIBODIES 114 9.2.3.1 Growing adoption of engineered antibodies to improve consistency, scalability, and performance of IVD assays 114 9.3 ANTIGENS & PROTEINS 115 9.3.1 RECOMBINANT ANTIGENS 117 9.3.1.1 Growing preference for scalable and consistent antigen production to support increasing IVD assay demand 117 9.3.2 NATIVE PROTEINS 119 9.3.2.1 Continued demand for biologically authentic proteins in sensitive assay development and clinically representative IVD applications 119 9.3.3 CALIBRATORS & STANDARDS 121 9.3.3.1 Increasing emphasis on assay standardization and traceability to drive demand for calibrators & reference materials 121 9.4 ENZYMES & SUBSTRATES 122 9.4.1 DETECTION ENZYMES 125 9.4.1.1 Increasing adoption of enzyme-based signal generation to improve sensitivity and quantitative performance of immunoassays 125 9.4.2 AMPLIFICATION ENZYMES 126 9.4.2.1 Growing adoption of molecular diagnostic testing to accelerate demand for high-performance amplification enzymes 126 9.4.3 SUBSTRATES & COENZYMES 128 9.4.3.1 Increasing need for optimized reaction components to enhance enzyme activity and diagnostic assay signal generation 128 9.5 OLIGONUCLEOTIDES & NUCLEIC ACIDS 130 9.5.1 PRIMERS & PROBES 132 9.5.1.1 Increasing adoption of PCR and multiplex molecular assays to drive demand for sequence-specific primers and probes 132 9.5.2 SYNTHETIC DNA/RNA 134 9.5.2.1 Growing use of synthetic DNA and RNA sequences to accelerate molecular assay development and validation 134 9.6 BEADS & PARTICLES 135 9.6.1 MAGNETIC BEADS 137 9.6.1.1 Growing adoption of automated magnetic-particle immunoassays to drive demand for high-performance magnetic beads 137 9.6.2 LATEX BEADS 139 9.6.2.1 Widespread use of latex particle-based agglutination and turbidimetric assays to sustain demand for latex beads 139 9.6.3 GOLD NANOPARTICLES 141 9.6.3.1 Increasing adoption of gold nanoparticle-based signal generation in rapid and visually readable diagnostic assays 141 9.7 MEMBRANES 142 9.7.1 NITROCELLULOSE MEMBRANES 144 9.7.1.1 High protein-binding capacity and controlled capillary flow to underpin nitrocellulose use across lateral flow and membrane-based immunodiagnostics 144 9.7.2 NYLON & PVDF MEMBRANES 146 9.7.2.1 Higher chemical resistance and specialized biomolecule immobilization requirements to sustain demand 146 9.7.3 GLASS FIBER PADS 148 9.7.3.1 Consistent sample and conjugate transport to strengthen role of glass fiber pads in lateral flow test construction 148 9.8 LABELS & DETECTION MATERIALS 150 9.8.1 FLUORESCENT DYES 152 9.8.1.1 Higher analytical sensitivity and instrument-based quantification to expand use of fluorescent detection in IVD 152 9.8.2 CHEMILUMINESCENT LABELS 154 9.8.2.1 Demand for ultra-sensitive immunoassays to sustain adoption of chemiluminescent labels 154 9.8.3 COLLOIDAL GOLD CONJUGATES 156 9.8.3.1 Established visual-readout capability and simplicity of lateral flow testing to sustain demand for colloidal gold conjugates 156 9.9 BUFFERS & DILUENTS 158 9.9.1 GREATER EMPHASIS ON REACTION STABILITY AND INTERFERENCE CONTROL TO SUPPORT RELIABLE IVD ASSAY PERFORMANCE 158 9.10 OTHER PRODUCTS 160 10 IVD RAW MATERIALS MARKET, BY TECHNOLOGY 163 10.1 INTRODUCTION 164 10.2 IMMUNOASSAY 164 10.2.1 INCREASING ADOPTION OF HIGH-SENSITIVITY, AUTOMATED IMMUNOASSAYS TO SUSTAIN DEMAND FOR RAW MATERIALS 164 10.3 MOLECULAR DIAGNOSTICS 166 10.3.1 EXPANSION OF PCR AND ISOTHERMAL AMPLIFICATION FORMATS TO INCREASE DEMAND FOR ENGINEERED POLYMERASES, MASTER MIXES, OLIGONUCLEOTIDES, AND NUCLEIC ACID CONTROLS 166 10.4 CLINICAL CHEMISTRY 168 10.4.1 INCREASING DEMAND FOR HIGH-QUALITY ENZYMES, PROTEINS, LIPOPROTEINS, AND REFERENCE MATERIALS TO SUPPORT AUTOMATED QUANTITATIVE TESTING 168 10.5 HEMATOLOGY 170 10.5.1 GROWING DEMAND FOR CELL-BASED REFERENCE MATERIALS AND BLOOD-DERIVED COMPONENTS TO STRENGTHEN RAW-MATERIAL REQUIREMENTS FOR HEMATOLOGY DIAGNOSTICS 170 10.6 MICROBIOLOGY & CULTURE 172 10.6.1 ADVANCES IN CULTURE-MEDIA FORMULATION AND MICROBIAL IDENTIFICATION TO STRENGTHEN DEMAND FOR SPECIALIZED MICROBIOLOGY RAW MATERIALS 172 10.7 COAGULATION TESTING 174 10.7.1 GREATER EMPHASIS ON FAST, STANDARDIZED MEASUREMENT OF CLOTTING AND FIBRINOLYSIS TO SHAPE RAW MATERIAL REQUIREMENTS IN COAGULATION DIAGNOSTICS 174 10.8 FLOW CYTOMETRY 176 10.8.1 MULTIPARAMETER CELLULAR ANALYSIS TO INCREASE DEMAND FOR HIGHLY SPECIFIC ANTIBODIES AND FLUORESCENT DETECTION MATERIALS 176 10.9 OTHER TECHNOLOGIES 178 11 IVD RAW MATERIALS MARKET, BY APPLICATION 181 11.1 INTRODUCTION 182 11.2 INFECTIOUS DISEASES 182 11.2.1 BROAD PATHOGEN COVERAGE AND FREQUENT DEMAND FOR RAPID, SENSITIVE TESTING TO DRIVE MARKET GROWTH 182 11.3 ONCOLOGY/CANCER MARKERS 184 11.3.1 MOLECULAR EXPANSION OF BIOMARKER-BASED CANCER DETECTION AND MONITORING TO INCREASE DEMAND FOR RAW MATERIALS 184 11.4 CARDIAC MARKERS 186 11.4.1 HIGH DISEASE PREVALENCE AND USE OF HIGH-SENSITIVITY BIOMARKERS TO STRENGTHEN DEMAND FOR CARDIAC-MARKER RAW MATERIALS 186 11.5 DIABETES & METABOLIC DISORDERS 188 11.5.1 EXPANDING BIOMARKER-BASED SCREENING TO SUSTAIN DEMAND FOR HBA1C, INSULIN, GLUCOSE, AND RELATED IVD RAW MATERIALS 188 11.6 AUTOIMMUNE DISEASES 190 11.6.1 GROWING RELIANCE ON AUTOANTIBODY-BASED TESTING TO SUPPORT DIAGNOSIS OF DIVERSE AUTOIMMUNE CONDITIONS AND EXPAND DEMAND FOR HIGHLY SPECIFIC IVD RAW MATERIALS 190 11.7 BLOOD SCREENING 192 11.7.1 MANDATORY SCREENING OF DONATED BLOOD AND NEED TO DETECT MULTIPLE TRANSFUSION-TRANSMISSIBLE INFECTIONS UNDERPIN DEMAND FOR DIVERSE IVD RAW MATERIALS 192 11.8 WOMEN’S HEALTH & FERTILITY 194 11.8.1 HIGH PREVALENCE OF INFERTILITY AND EXPANDING HORMONE-BASED REPRODUCTIVE TESTING TO SUSTAIN THE DEMAND 194 11.9 GENETIC & RARE DISEASE TESTING 196 11.9.1 EXPANSION OF MOLECULAR AND GENETIC TESTING TO ADDRESS A LARGE AND CLINICALLY DIVERSE POPULATION 196 11.10 OTHER APPLICATIONS 198 12 IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE 201 12.1 INTRODUCTION 202 12.2 IN-HOUSE MANUFACTURING 202 12.2.1 GREATER CONTROL OVER CRITICAL REAGENTS AND ASSAY PERFORMANCE TO SUSTAIN IN-HOUSE PRODUCTION 202 12.3 THIRD-PARTY SUPPLY 204 12.3.1 OUTSOURCING SPECIALIZED CAPABILITIES TO IMPROVE FLEXIBILITY AND ACCELERATE IVD DEVELOPMENT 204 13 IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN 207 13.1 INTRODUCTION 208 13.2 BIOLOGICAL/NATURAL SOURCES 208 13.2.1 ANIMAL-DERIVED 210 13.2.1.1 Established assay performance and broad availability to sustain use of animal-derived IVD raw materials 210 13.2.2 HUMAN-DERIVED 212 13.2.2.1 Clinical relevance and patient-like matrices to sustain demand for human-derived IVD raw materials 212 13.3 RECOMBINANT/SYNTHETIC SOURCES 214 13.3.1 E. COLI-EXPRESSED 217 13.3.1.1 Scalable production and strong suitability for non-glycosylated proteins to support E. coli-based recombinant IVD materials 217 13.3.2 CHO-EXPRESSED 219 13.3.2.1 Mammalian expression for structurally complex biomarkers to improve assay relevance and performance 219 13.3.3 CHEMICALLY SYNTHESIZED 221 13.3.3.1 Precisely defined composition and scalable manufacturing to expand the role of synthetic materials in IVD 221 13.4 OTHER SOURCES 223 14 IVD RAW MATERIALS MARKET, BY END USER 225 14.1 INTRODUCTION 226 14.2 IVD MANUFACTURERS 226 14.2.1 EXPANDING ASSAY PORTFOLIOS AND TIGHTER CONTROL OF CRITICAL COMPONENTS TO DRIVE RAW-MATERIAL CONSUMPTION 226 14.3 CONTRACT RESEARCH ORGANIZATIONS 228 14.3.1 INCREASING OUTSOURCING OF ASSAY DEVELOPMENT AND VALIDATION TO ACCELERATE IVD COMMERCIALIZATION 228 14.4 ACADEMIC & RESEARCH INSTITUTES 230 14.4.1 GROWING TRANSLATIONAL RESEARCH AND ASSAY DEVELOPMENT TO EXPAND CONSUMPTION OF SPECIALIZED IVD RAW MATERIALS 230 14.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 232 14.5.1 INTEGRATION OF DIAGNOSTICS INTO DRUG DEVELOPMENT TO INCREASE DEMAND FOR BIOMARKER AND ASSAY COMPONENTS 232 14.6 OTHER END USERS 234 15 IVD RAW MATERIALS MARKET, BY REGION 237 15.1 INTRODUCTION 238 15.2 NORTH AMERICA 238 15.2.1 US 246 15.2.1.1 Increasing demand for advanced diagnostics and a mature reimbursement framework to drive market 246 15.2.2 CANADA 252 15.2.2.1 Rising disease prevalence and demand for early diagnoses drive market growth 252 15.3 EUROPE 259 15.3.1 GERMANY 266 15.3.1.1 Increasing investments in life sciences and advanced diagnostics to propel demand for IVD raw materials 266 15.3.2 UK 273 15.3.2.1 Rising adoption of genomic testing and advanced diagnostics to support demand growth 273 15.3.3 FRANCE 280 15.3.3.1 High healthcare expenditure and continued investment in genomic medicine to drive market 280 15.3.4 ITALY 287 15.3.4.1 Growing geriatric population and increasing burden of chronic diseases to boost demand for IVD raw materials 287 15.3.5 SPAIN 294 15.3.5.1 Increasing adoption of genomic testing and advanced diagnostics to support the market 294 15.3.6 REST OF EUROPE 301 15.4 ASIA PACIFIC 307 15.4.1 CHINA 315 15.4.1.1 Growing focus on preventive care and localization of IVD raw materials to boost market 315 15.4.2 JAPAN 321 15.4.2.1 Increasing research investment and adoption of advanced diagnostics to support market growth 321 15.4.3 INDIA 328 15.4.3.1 Rising incidence of diabetes and cancer and increasing localization of IVD manufacturing to augment growth 328 15.4.4 REST OF ASIA PACIFIC 334 15.5 LATIN AMERICA 341 15.5.1 INCREASING HEALTHCARE INVESTMENT, DISEASE BURDEN, AND EXPANSION OF DIAGNOSTIC ACCESS TO SUPPORT MARKET GROWTH 341 15.6 MIDDLE EAST & AFRICA 347 15.6.1 INCREASING HEALTHCARE INVESTMENT, PREVENTIVE SCREENING, AND DIAGNOSTIC INFRASTRUCTURE TO SUPPORT MARKET GROWTH 347 16 IVD RAW MATERIALS MARKET: VOLUME ANALYSIS 355 16.1 INTRODUCTION 355 16.2 GLOBAL: NAT BASED PCR EQUIPMENT SOLD, 2024–2031 (THOUSAND UNITS) 355 17 COMPETITIVE LANDSCAPE 356 17.1 INTRODUCTION 356 17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 356 17.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN IVD RAW MATERIALS MARKET 356 17.3 REVENUE ANALYSIS, 2023–2025 357 17.4 MARKET SHARE ANALYSIS, 2025 358 17.4.1 THIRD-PARTY SUPPLIERS MARKET SHARE ANALYSIS, 2025 358 17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 360 17.5.1 STARS 360 17.5.2 EMERGING LEADERS 360 17.5.3 PERVASIVE PLAYERS 360 17.5.4 PARTICIPANTS 360 17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 362 17.5.5.1 Company footprint 362 17.5.5.2 Region footprint 362 17.5.5.3 Product type footprint 363 17.5.5.4 End-user footprint 364 17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 364 17.6.1 PROGRESSIVE COMPANIES 364 17.6.2 RESPONSIVE COMPANIES 364 17.6.3 DYNAMIC COMPANIES 365 17.6.4 STARTING BLOCKS 365 17.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 366 17.6.5.1 Detailed list of key startups/SMEs 366 17.6.5.2 Competitive benchmarking of startups/SMEs (1/2) 366 17.6.5.3 Competitive benchmarking of startups/SMEs (2/2) 367 17.7 COMPANY VALUATION & FINANCIAL METRICS 367 17.7.1 FINANCIAL METRICS 367 17.7.2 COMPANY VALUATION 368 17.8 BRAND/PRODUCT COMPARISON 369 17.9 COMPETITIVE SCENARIO 370 17.9.1 PRODUCT LAUNCHES & APPROVALS 370 17.9.2 DEALS 370 18 COMPANY PROFILES 372 18.1 KEY PLAYERS 372 18.1.1 MERCK KGAA 372 18.1.1.1 Business overview 372 18.1.1.2 Products offered 373 18.1.1.3 Recent developments 380 18.1.1.3.1 Product launches & approvals 380 18.1.1.3.2 Deals 380 18.1.1.4 MnM view 380 18.1.1.4.1 Key strengths 380 18.1.1.4.2 Strategic choices 380 18.1.1.4.3 Weaknesses and competitive threats 381 18.1.2 THERMO FISHER SCIENTIFIC 382 18.1.2.1 Business overview 382 18.1.2.2 Products offered 383 18.1.2.3 Recent developments 389 18.1.2.3.1 Product enhancements 389 18.1.2.3.2 Deals 389 18.1.2.4 MnM view 389 18.1.2.4.1 Key strengths 389 18.1.2.4.2 Strategic choices 390 18.1.2.4.3 Weaknesses & competitive threats 390 18.1.3 BIO-TECHNE CORPORATION 391 18.1.3.1 Business overview 391 18.1.3.2 Products & services offered 392 18.1.3.3 Recent developments 399 18.1.3.3.1 Product launches & approvals 399 18.1.3.3.2 Deals 399 18.1.3.4 MnM view 399 18.1.3.4.1 Key strengths 399 18.1.3.4.2 Strategic choices 399 18.1.3.4.3 Weaknesses & competitive threats 400 18.1.4 FAPON BIOTECH 401 18.1.4.1 Business overview 401 18.1.4.2 Products & services offered 402 18.1.4.3 Recent developments 407 18.1.4.3.1 Product launches & approvals 407 18.1.4.4 MnM view 407 18.1.4.4.1 Key strengths 407 18.1.4.4.2 Strategic choices 407 18.1.4.4.3 Weaknesses & competitive threats 407 18.1.5 MERIDIAN BIOSCIENCE 408 18.1.5.1 Business overview 408 18.1.5.2 Products offered 409 18.1.5.3 Recent developments 415 18.1.5.3.1 Product launches 415 18.1.5.3.2 Deals 415 18.1.5.4 MnM view 415 18.1.5.4.1 Key strengths 415 18.1.5.4.2 Strategic choices 415 18.1.5.4.3 Weaknesses & competitive threats 415 18.1.6 MEDIX BIOCHEMICA 416 18.1.6.1 Business overview 416 18.1.6.2 Products & services offered 417 18.1.6.3 Recent developments 422 18.1.6.3.1 Deals 422 18.1.6.3.2 Expansions 423 18.1.7 ROCHE CUSTOMBIOTECH 424 18.1.7.1 Business overview 424 18.1.7.2 Products & services offered 425 18.1.8 DANAHER CORPORATION 431 18.1.8.1 Business overview 431 18.1.8.2 Products & services offered 432 18.1.8.3 Recent developments 440 18.1.8.3.1 Deals 440 18.1.9 SARTORIUS AG 441 18.1.9.1 Business overview 441 18.1.9.2 Products offered 442 18.1.10 HYTEST LTD. 445 18.1.10.1 Business overview 445 18.1.10.2 Products offered 445 18.1.11 TOYOBO CO., LTD. 453 18.1.11.1 Business overview 453 18.1.11.2 Products offered 454 18.1.12 LGC BIOSEARCH TECHNOLOGIES 460 18.1.12.1 Business overview 460 18.1.12.2 Products offered 461 18.2 OTHER PLAYERS 466 18.2.1 BBI SOLUTIONS 466 18.2.2 SURMODICS IVD 467 18.2.3 AHLSTROM OYJ 468 18.2.4 BANGS LABORATORIES 469 18.2.5 SCRIPPS LABORATORIES, INC. 470 18.2.6 MIKROGEN GMBH 471 18.2.7 ADVANCED MICRODEVICES PVT. LTD. 472 18.2.8 SEKISUI DIAGNOSTICS 473 18.2.9 RANDOX LABORATORIES LTD. 474 18.2.10 HIMEDIA LABORATORIES 475 18.2.11 SINO BIOLOGICAL 476 18.2.12 BIOSYNTH 477 18.2.13 NEW ENGLAND BIOLABS, INC. 478 19 RESEARCH METHODOLOGY 479 19.1 RESEARCH DATA 479 19.2 SECONDARY DATA 480 19.2.1 LIST OF SECONDARY SOURCES 480 19.2.2 PRIMARY DATA 481 19.2.2.1 Key data from primary sources 482 19.2.2.2 Breakdown of primary interviews 484 19.3 MARKET SIZE ESTIMATION 484 19.3.1 TOTAL MARKET SIZE: IVD RAW MATERIALS MARKET 485 19.3.2 BOTTOM-UP APPROACH 485 19.3.2.1 Approach 2: Study of annual reports and investor presentations 485 19.3.2.2 Approach 3: Primary interviews 486 19.3.2.3 Growth forecast 486 19.3.3 TOP-DOWN APPROACH 487 19.4 DATA TRIANGULATION 487 19.5 RESEARCH ASSUMPTIONS 488 19.5.1 STUDY-RELATED ASSUMPTIONS 488 19.6 STUDY ASSUMPTIONS 489 19.6.1 GROWTH RATE ASSUMPTIONS 490 19.7 RESEARCH LIMITATIONS 490 19.8 RISK ASSESSMENT 490 20 APPENDIX 491 20.1 DISCUSSION GUIDE 491 20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 496 20.3 CUSTOMIZATION OPTIONS 498 20.4 RELATED REPORTS 498 20.5 AUTHOR DETAILS 499

圖表清單 List of Tables & Figures

TABLE 1 RECENT INDICATORS SUPPORTING PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS 57 TABLE 2 RECENT INDUSTRY DEVELOPMENTS SUPPORTING RECOMBINANT BIOMOLECULE ADOPTION 57 TABLE 3 PORTER’S FIVE FORCES ANALYSIS: IMPACT ANALYSIS 69 TABLE 4 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 70 TABLE 5 NORTH AMERICA: MACROECONOMIC INDICATORS 71 TABLE 6 EUROPE: MACROECONOMIC INDICATORS 71 TABLE 7 ASIA PACIFIC: MACROECONOMIC INDICATORS 72 TABLE 8 LATIN AMERICA: MACROECONOMIC INDICATORS 72 TABLE 9 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 72 TABLE 10 IVD RAW MATERIALS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 75 TABLE 11 AVERAGE SELLING PRICE OF IVD RAW MATERIALS, BY REGION, 2024–2026 (USD) 76 TABLE 12 AVERAGE SELLING PRICE OF IVD RAW MATERIALS, KEY PLAYER, 2024–2026 (USD) 77 TABLE 13 IMPORT DATA FOR HS CODE 300213-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 78 TABLE 14 EXPORT DATA FOR HS CODE 300213-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 78 TABLE 15 IVD RAW MATERIALS MARKET: KEY CONFERENCES AND EVENTS, 2026–2027 79 TABLE 16 US-ADJUSTED RECIPROCAL TARIFF RATES 81 TABLE 17 IVD RAW MATERIALS MARKET—KEY TECHNOLOGIES 84 TABLE 18 KEY PATENTS IN IVD RAW MATERIALS, 2023–2026 88 TABLE 19 KEY COMPANIES IMPLEMENTING AI IN IVD RAW MATERIALS MARKET 91 TABLE 20 US: KEY REGULATORY EXPECTATIONS FOR IVD RAW MATERIAL SUPPLIERS 93 TABLE 21 CANADA: KEY REGULATORY EXPECTATIONS FOR IVD RAW MATERIAL SUPPLIERS 93 TABLE 22 JAPAN: REGULATORY EXPECTATIONS FOR IVD RAW MATERIAL SUPPLIERS 95 TABLE 23 CHINA: REGULATORY EXPECTATIONS FOR IVD RAW MATERIAL SUPPLIERS 96 TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97 TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97 TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97 TABLE 27 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98 TABLE 28 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98 TABLE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 102 TABLE 30 KEY BUYING CRITERIA, BY END USER 102 TABLE 31 ADOPTION BARRIERS & INTERNAL CHALLENGES 103 TABLE 32 IVD RAW MATERIALS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 104 TABLE 33 IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 107 TABLE 34 ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 108 TABLE 35 ANTIBODIES MARKET, BY REGION, 2024–2031 (USD MILLION) 109 TABLE 36 NORTH AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 109 TABLE 37 EUROPE: ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 109 TABLE 38 ASIA PACIFIC: ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 110 TABLE 39 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2024–2031 (USD MILLION) 111 TABLE 40 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 111 TABLE 41 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 111 TABLE 42 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 112 TABLE 43 POLYCLONAL ANTIBODIES MARKET, BY REGION, 2024–2031 (USD MILLION) 112 TABLE 44 NORTH AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 113 TABLE 45 EUROPE: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 113 TABLE 46 ASIA PACIFIC: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 113 TABLE 47 RECOMBINANT ANTIBODIES MARKET, BY REGION, 2024–2031 (USD MILLION) 114 TABLE 48 NORTH AMERICA: RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 114 TABLE 49 EUROPE: RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 115 TABLE 50 ASIA PACIFIC: RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 115 TABLE 51 ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 116 TABLE 52 ANTIGENS & PROTEINS MARKET, BY REGION, 2024–2031 (USD MILLION) 116 TABLE 53 NORTH AMERICA: ANTIGENS & PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 116 TABLE 54 EUROPE: ANTIGENS & PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 117 TABLE 55 ASIA PACIFIC: ANTIGENS & PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 117 TABLE 56 RECOMBINANT ANTIGENS MARKET, BY REGION, 2024–2031 (USD MILLION) 118 TABLE 57 NORTH AMERICA: RECOMBINANT ANTIGENS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 118 TABLE 58 EUROPE: RECOMBINANT ANTIGENS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 118 TABLE 59 ASIA PACIFIC: RECOMBINANT ANTIGENS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 119 TABLE 60 NATIVE PROTEINS MARKET, BY REGION, 2024–2031 (USD MILLION) 119 TABLE 61 NORTH AMERICA: NATIVE PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 120 TABLE 62 EUROPE: NATIVE PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 120 TABLE 63 ASIA PACIFIC: NATIVE PROTEINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 120 TABLE 64 CALIBRATORS & STANDARDS MARKET, BY REGION, 2024–2031 (USD MILLION) 121 TABLE 65 NORTH AMERICA: CALIBRATORS & STANDARDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 121 TABLE 66 EUROPE: CALIBRATORS & STANDARDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 122 TABLE 67 ASIA PACIFIC: CALIBRATORS & STANDARDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 122 TABLE 68 ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 123 TABLE 69 ENZYMES & SUBSTRATES MARKET, BY REGION, 2024–2031 (USD MILLION) 123 TABLE 70 NORTH AMERICA: ENZYMES & SUBSTRATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 124 TABLE 71 EUROPE: ENZYMES & SUBSTRATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 124 TABLE 72 ASIA PACIFIC: ENZYMES & SUBSTRATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 124 TABLE 73 DETECTION ENZYMES MARKET, BY REGION, 2024–2031 (USD MILLION) 125 TABLE 74 NORTH AMERICA: DETECTION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 125 TABLE 75 EUROPE: DETECTION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 126 TABLE 76 ASIA PACIFIC: DETECTION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 126 TABLE 77 AMPLIFICATION ENZYMES MARKET, BY REGION, 2024–2031 (USD MILLION) 127 TABLE 78 NORTH AMERICA: AMPLIFICATION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127 TABLE 79 EUROPE: AMPLIFICATION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 128 TABLE 80 ASIA PACIFIC: AMPLIFICATION ENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 128 TABLE 81 SUBSTRATES & COENZYMES MARKET, BY REGION, 2024–2031 (USD MILLION) 129 TABLE 82 NORTH AMERICA: SUBSTRATES & COENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 83 EUROPE: SUBSTRATES & COENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 84 ASIA PACIFIC: SUBSTRATES & COENZYMES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 130 TABLE 85 OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 130 TABLE 86 OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY REGION, 2024–2031 (USD MILLION) 131 TABLE 87 NORTH AMERICA: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 131 TABLE 88 EUROPE: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 131 TABLE 89 ASIA PACIFIC: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 90 PRIMERS & PROBES MARKET, BY REGION, 2024–2031 (USD MILLION) 132 TABLE 91 NORTH AMERICA: PRIMERS & PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 133 TABLE 92 EUROPE: PRIMERS & PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 133 TABLE 93 ASIA PACIFIC: PRIMERS & PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 133 TABLE 94 SYNTHETIC DNA/RNA MARKET, BY REGION, 2024–2031 (USD MILLION) 134 TABLE 95 NORTH AMERICA: SYNTHETIC DNA/RNA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 96 EUROPE: SYNTHETIC DNA/RNA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135 TABLE 97 ASIA PACIFIC: SYNTHETIC DNA/RNA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135 TABLE 98 BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 136 TABLE 99 BEADS & PARTICLES MARKET, BY REGION, 2024–2031 (USD MILLION) 136 TABLE 100 NORTH AMERICA: BEADS & PARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 136 TABLE 101 EUROPE: BEADS & PARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 102 ASIA PACIFIC: BEADS & PARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 103 MAGNETIC BEADS MARKET, BY REGION, 2024–2031 (USD MILLION) 138 TABLE 104 NORTH AMERICA: MAGNETIC BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138 TABLE 105 EUROPE: MAGNETIC BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138 TABLE 106 ASIA PACIFIC: MAGNETIC BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 139 TABLE 107 LATEX BEADS MARKET, BY REGION, 2024–2031 (USD MILLION) 139 TABLE 108 NORTH AMERICA: LATEX BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140 TABLE 109 EUROPE: LATEX BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140 TABLE 110 ASIA PACIFIC: LATEX BEADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140 TABLE 111 GOLD NANOPARTICLES MARKET, BY REGION, 2024–2031 (USD MILLION) 141 TABLE 112 NORTH AMERICA: GOLD NANOPARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 113 EUROPE: GOLD NANOPARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 114 ASIA PACIFIC: GOLD NANOPARTICLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 115 MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 143 TABLE 116 MEMBRANES MARKET, BY REGION, 2024–2031 (USD MILLION) 143 TABLE 117 NORTH AMERICA: MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 143 TABLE 118 EUROPE: MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144 TABLE 119 ASIA PACIFIC: MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144 TABLE 120 NITROCELLULOSE MEMBRANES MARKET, BY REGION, 2024–2031 (USD MILLION) 145 TABLE 121 NORTH AMERICA: NITROCELLULOSE MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145 TABLE 122 EUROPE: NITROCELLULOSE MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 123 ASIA PACIFIC: NITROCELLULOSE MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 124 NYLON & PVDF MEMBRANES MARKET, BY REGION, 2024–2031 (USD MILLION) 147 TABLE 125 NORTH AMERICA: NYLON & PVDF MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 126 EUROPE: NYLON & PVDF MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 127 ASIA PACIFIC: NYLON & PVDF MEMBRANES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 128 GLASS FIBER PADS MARKET, BY REGION, 2024–2031 (USD MILLION) 149 TABLE 129 NORTH AMERICA: GLASS FIBER PADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 149 TABLE 130 EUROPE: GLASS FIBER PADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 131 ASIA PACIFIC: GLASS FIBER PADS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 132 LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 151 TABLE 133 LABELS & DETECTION MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION) 151 TABLE 134 NORTH AMERICA: LABELS & DETECTION MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151 TABLE 135 EUROPE: LABELS & DETECTION MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152 TABLE 136 ASIA PACIFIC: LABELS & DETECTION MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152 TABLE 137 FLUORESCENT DYES MARKET, BY REGION, 2024–2031 (USD MILLION) 153 TABLE 138 NORTH AMERICA: FLUORESCENT DYES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 139 EUROPE: FLUORESCENT DYES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 140 ASIA PACIFIC: FLUORESCENT DYES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 141 CHEMILUMINESCENT LABELS MARKET, BY REGION, 2024–2031 (USD MILLION) 155 TABLE 142 NORTH AMERICA: CHEMILUMINESCENT LABELS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 143 EUROPE: CHEMILUMINESCENT LABELS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 156 TABLE 144 ASIA PACIFIC: CHEMILUMINESCENT LABELS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 156 TABLE 145 COLLOIDAL GOLD CONJUGATES MARKET, BY REGION, 2024–2031 (USD MILLION) 157 TABLE 146 NORTH AMERICA: COLLOIDAL GOLD CONJUGATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 147 EUROPE: COLLOIDAL GOLD CONJUGATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 158 TABLE 148 ASIA PACIFIC: COLLOIDAL GOLD CONJUGATES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 158 TABLE 149 BUFFERS & DILUENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 159 TABLE 150 NORTH AMERICA: BUFFERS & DILUENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 159 TABLE 151 EUROPE: BUFFERS & DILUENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 152 ASIA PACIFIC: BUFFERS & DILUENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 153 IVD RAW MATERIALS MARKET FOR OTHER PRODUCTS, BY REGION, 2024–2031 (USD MILLION) 161 TABLE 154 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 161 TABLE 155 EUROPE: IVD RAW MATERIALS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 162 TABLE 156 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 162 TABLE 157 IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 164 TABLE 158 IMMUNOASSAY MARKET, BY REGION, 2024–2031 (USD MILLION) 165 TABLE 159 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 165 TABLE 160 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 166 TABLE 161 ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 166 TABLE 162 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION) 167 TABLE 163 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 164 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 168 TABLE 165 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 168 TABLE 166 CLINICAL CHEMISTRY MARKET, BY REGION, 2024–2031 (USD MILLION) 169 TABLE 167 NORTH AMERICA: CLINICAL CHEMISTRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 169 TABLE 168 EUROPE: CLINICAL CHEMISTRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 169 ASIA PACIFIC: CLINICAL CHEMISTRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 170 HEMATOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 171 TABLE 171 NORTH AMERICA: HEMATOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 172 EUROPE: HEMATOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 172 TABLE 173 ASIA PACIFIC: HEMATOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 172 TABLE 174 MICROBIOLOGY & CULTURE MARKET, BY REGION, 2024–2031 (USD MILLION) 173 TABLE 175 NORTH AMERICA: MICROBIOLOGY & CULTURE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 173 TABLE 176 EUROPE: MICROBIOLOGY & CULTURE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 177 ASIA PACIFIC: MICROBIOLOGY & CULTURE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 178 COAGULATION TESTING MARKET, BY REGION, 2024–2031 (USD MILLION) 175 TABLE 179 NORTH AMERICA: COAGULATION TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 175 TABLE 180 EUROPE: COAGULATION TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 181 ASIA PACIFIC: COAGULATION TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 182 FLOW CYTOMETRY MARKET, BY REGION, 2024–2031 (USD MILLION) 177 TABLE 183 NORTH AMERICA: FLOW CYTOMETRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 177 TABLE 184 EUROPE: FLOW CYTOMETRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 178 TABLE 185 ASIA PACIFIC: FLOW CYTOMETRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 178 TABLE 186 OTHER TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 179 TABLE 187 NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 179 TABLE 188 EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 189 ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 190 IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 182 TABLE 191 IVD RAW MATERIALS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 183 TABLE 192 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 193 EUROPE: IVD RAW MATERIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 184 TABLE 194 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 184 TABLE 195 IVD RAW MATERIALS MARKET FOR ONCOLOGY/CANCER MARKERS, BY REGION, 2024–2031 (USD MILLION) 185 TABLE 196 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR ONCOLOGY/CANCER MARKERS, BY COUNTRY, 2024–2031 (USD MILLION) 185 TABLE 197 EUROPE: IVD RAW MATERIALS MARKET FOR ONCOLOGY/CANCER MARKERS, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 198 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR ONCOLOGY/CANCER MARKERS, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 199 IVD RAW MATERIALS MARKET FOR CARDIAC MARKERS, BY REGION, 2024–2031 (USD MILLION) 187 TABLE 200 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR CARDIAC MARKERS, BY COUNTRY, 2024–2031 (USD MILLION) 187 TABLE 201 EUROPE: IVD RAW MATERIALS MARKET FOR CARDIAC MARKERS, BY COUNTRY, 2024–2031 (USD MILLION) 188 TABLE 202 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR CARDIAC MARKERS, BY COUNTRY, 2024–2031 (USD MILLION) 188 TABLE 203 IVD RAW MATERIALS MARKET FOR DIABETES & METABOLIC DISORDERS, BY REGION, 2024–2031 (USD MILLION) 189 TABLE 204 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR DIABETES & METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 205 EUROPE: IVD RAW MATERIALS MARKET FOR DIABETES & METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 190 TABLE 206 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR DIABETES & METABOLIC DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 190 TABLE 207 IVD RAW MATERIALS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2024–2031 (USD MILLION) 191 TABLE 208 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 191 TABLE 209 EUROPE: IVD RAW MATERIALS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 192 TABLE 210 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 192 TABLE 211 IVD RAW MATERIALS MARKET FOR BLOOD SCREENING, BY REGION, 2024–2031 (USD MILLION) 193 TABLE 212 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 213 EUROPE: IVD RAW MATERIALS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 214 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 215 IVD RAW MATERIALS MARKET FOR WOMEN’S HEALTH & FERTILITY, BY REGION, 2024–2031 (USD MILLION) 195 TABLE 216 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR WOMEN’S HEALTH & FERTILITY, BY COUNTRY, 2024–2031 (USD MILLION) 195 TABLE 217 EUROPE: IVD RAW MATERIALS MARKET FOR WOMEN’S HEALTH & FERTILITY, BY COUNTRY, 2024–2031 (USD MILLION) 196 TABLE 218 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR WOMEN’S HEALTH & FERTILITY, BY COUNTRY, 2024–2031 (USD MILLION) 196 TABLE 219 IVD RAW MATERIALS MARKET FOR GENETIC & RARE DISEASE TESTING, BY REGION, 2024–2031 (USD MILLION) 197 TABLE 220 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR GENETIC & RARE DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 197 TABLE 221 EUROPE: IVD RAW MATERIALS MARKET FOR GENETIC & RARE DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 198 TABLE 222 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR GENETIC & RARE DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 198 TABLE 223 IVD RAW MATERIALS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 199 TABLE 224 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 199 TABLE 225 EUROPE: IVD RAW MATERIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 226 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 227 IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 202 TABLE 228 IN-HOUSE MANUFACTURING MARKET, BY REGION, 2024–2031 (USD MILLION) 203 TABLE 229 NORTH AMERICA: IN-HOUSE MANUFACTURING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 203 TABLE 230 EUROPE: IN-HOUSE MANUFACTURING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 203 TABLE 231 ASIA PACIFIC: IN-HOUSE MANUFACTURING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 204 TABLE 232 THIRD-PARTY SUPPLY MARKET, BY REGION, 2024–2031 (USD MILLION) 205 TABLE 233 NORTH AMERICA: THIRD-PARTY SUPPLY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 205 TABLE 234 EUROPE: THIRD-PARTY SUPPLY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 205 TABLE 235 ASIA PACIFIC: THIRD-PARTY SUPPLY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 206 TABLE 236 IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 208 TABLE 237 BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 209 TABLE 238 BIOLOGICAL/NATURAL SOURCES MARKET, BY REGION, 2024–2031 (USD MILLION) 209 TABLE 239 NORTH AMERICA: BIOLOGICAL/NATURAL SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 209 TABLE 240 EUROPE: BIOLOGICAL/NATURAL SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 210 TABLE 241 ASIA PACIFIC: BIOLOGICAL/NATURAL SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 210 TABLE 242 ANIMAL-DERIVED IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION) 211 TABLE 243 NORTH AMERICA: ANIMAL-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 211 TABLE 244 EUROPE: ANIMAL-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 212 TABLE 245 ASIA PACIFIC: ANIMAL-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 212 TABLE 246 HUMAN-DERIVED IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION) 213 TABLE 247 NORTH AMERICA: HUMAN-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 213 TABLE 248 EUROPE: HUMAN-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 214 TABLE 249 ASIA PACIFIC: HUMAN-DERIVED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 214 TABLE 250 RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 251 RECOMBINANT/SYNTHETIC SOURCES MARKET, BY REGION, 2024–2031 (USD MILLION) 215 TABLE 252 NORTH AMERICA: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 216 TABLE 253 EUROPE: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 216 TABLE 254 ASIA PACIFIC: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 216 TABLE 255 E. COLI-EXPRESSED IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION) 217 TABLE 256 NORTH AMERICA: E. COLI-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 218 TABLE 257 EUROPE: E. COLI-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 218 TABLE 258 ASIA PACIFIC: E. COLI-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 218 TABLE 259 CHO-EXPRESSED IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION) 219 TABLE 260 NORTH AMERICA: CHO-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 220 TABLE 261 EUROPE: CHO-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 220 TABLE 262 ASIA PACIFIC: CHO-EXPRESSED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 220 TABLE 263 CHEMICALLY SYNTHESIZED IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION) 221 TABLE 264 NORTH AMERICA: CHEMICALLY SYNTHESIZED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 222 TABLE 265 EUROPE: CHEMICALLY SYNTHESIZED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 222 TABLE 266 ASIA PACIFIC: CHEMICALLY SYNTHESIZED IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 222 TABLE 267 OTHER IVD RAW MATERIAL SOURCES MARKET, BY REGION, 2024–2031 (USD MILLION) 223 TABLE 268 NORTH AMERICA: OTHER IVD RAW MATERIAL SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 223 TABLE 269 EUROPE: OTHER IVD RAW MATERIAL SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 224 TABLE 270 ASIA PACIFIC: IVD RAW MATERIAL OTHER SOURCES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 224 TABLE 271 IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 226 TABLE 272 IVD RAW MATERIALS MARKET FOR IVD MANUFACTURERS, BY REGION, 2024–2031 (USD MILLION) 227 TABLE 273 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR IVD MANUFACTURERS, BY COUNTRY, 2024–2031 (USD MILLION) 227 TABLE 274 EUROPE: IVD RAW MATERIALS MARKET FOR IVD MANUFACTURERS, BY COUNTRY, 2024–2031 (USD MILLION) 228 TABLE 275 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR IVD MANUFACTURERS, BY COUNTRY, 2024–2031 (USD MILLION) 228 TABLE 276 IVD RAW MATERIALS MARKET FOR CROS, BY REGION, 2024–2031 (USD MILLION) 229 TABLE 277 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR CROS, BY COUNTRY, 2024–2031 (USD MILLION) 229 TABLE 278 EUROPE: IVD RAW MATERIALS MARKET FOR CROS, BY COUNTRY, 2024–2031 (USD MILLION) 230 TABLE 279 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR CROS, BY COUNTRY, 2024–2031 (USD MILLION) 230 TABLE 280 IVD RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 231 TABLE 281 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 231 TABLE 282 EUROPE: IVD RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 232 TABLE 283 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 232 TABLE 284 IVD RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 233 TABLE 285 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 233 TABLE 286 EUROPE: IVD RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 234 TABLE 287 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 234 TABLE 288 IVD RAW MATERIALS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 235 TABLE 289 NORTH AMERICA: IVD RAW MATERIALS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 235 TABLE 290 EUROPE: IVD RAW MATERIALS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 236 TABLE 291 ASIA PACIFIC: IVD RAW MATERIALS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 236 TABLE 292 IVD RAW MATERIALS MARKET, BY REGION, 2024–2031 (USD MILLION) 238 TABLE 293 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 240 TABLE 294 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 241 TABLE 295 NORTH AMERICA: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 296 NORTH AMERICA: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 242 TABLE 297 NORTH AMERICA: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 242 TABLE 298 NORTH AMERICA: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 242 TABLE 299 NORTH AMERICA: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 300 NORTH AMERICA: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 301 NORTH AMERICA: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 302 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 244 TABLE 303 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 244 TABLE 304 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 245 TABLE 305 NORTH AMERICA: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 245 TABLE 306 NORTH AMERICA: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 245 TABLE 307 NORTH AMERICA: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 246 TABLE 308 US: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 247 TABLE 309 US: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 310 US: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 311 US: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 312 US: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 313 US: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 314 US: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 315 US: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 316 US: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 250 TABLE 317 US: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 250 TABLE 318 US: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 251 TABLE 319 US: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 251 TABLE 320 US: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 321 US: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 252 TABLE 322 US: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 252 TABLE 323 CANADA: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 253 TABLE 324 CANADA: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 254 TABLE 325 CANADA: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 254 TABLE 326 CANADA: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 254 TABLE 327 CANADA: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 328 CANADA: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 329 CANADA: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 330 CANADA: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 331 CANADA: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 256 TABLE 332 CANADA: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 257 TABLE 333 CANADA: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 257 TABLE 334 CANADA: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 258 TABLE 335 CANADA: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 258 TABLE 336 CANADA: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 258 TABLE 337 CANADA: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 259 TABLE 338 EUROPE: IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 260 TABLE 339 EUROPE: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 261 TABLE 340 EUROPE: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 261 TABLE 341 EUROPE: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 342 EUROPE: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 343 EUROPE: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 344 EUROPE: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 345 EUROPE: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 346 EUROPE: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 347 EUROPE: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 264 TABLE 348 EUROPE: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 264 TABLE 349 EUROPE: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 265 TABLE 350 EUROPE: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 265 TABLE 351 EUROPE: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 352 EUROPE: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 353 EUROPE: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 266 TABLE 354 GERMANY: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 268 TABLE 355 GERMANY: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 268 TABLE 356 GERMANY: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 269 TABLE 357 GERMANY: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 269 TABLE 358 GERMANY: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 269 TABLE 359 GERMANY: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 360 GERMANY: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 361 GERMANY: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 362 GERMANY: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 271 TABLE 363 GERMANY: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 271 TABLE 364 GERMANY: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 272 TABLE 365 GERMANY: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 272 TABLE 366 GERMANY: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 272 TABLE 367 GERMANY: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 273 TABLE 368 GERMANY: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 273 TABLE 369 UK: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 275 TABLE 370 UK: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 371 UK: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 372 UK: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 373 UK: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 374 UK: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 375 UK: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 376 UK: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 377 UK: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 278 TABLE 378 UK: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 278 TABLE 379 UK: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 279 TABLE 380 UK: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 279 TABLE 381 UK: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 279 TABLE 382 UK: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 383 UK: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 280 TABLE 384 FRANCE: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 282 TABLE 385 FRANCE: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 282 TABLE 386 FRANCE: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 387 FRANCE: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 388 FRANCE: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 389 FRANCE: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 284 TABLE 390 FRANCE: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 284 TABLE 391 FRANCE: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 284 TABLE 392 FRANCE: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 285 TABLE 393 FRANCE: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 285 TABLE 394 FRANCE: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 286 TABLE 395 FRANCE: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 286 TABLE 396 FRANCE: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 286 TABLE 397 FRANCE: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 398 FRANCE: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 287 TABLE 399 ITALY: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 289 TABLE 400 ITALY: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 289 TABLE 401 ITALY: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 290 TABLE 402 ITALY: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 290 TABLE 403 ITALY: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 290 TABLE 404 ITALY: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 291 TABLE 405 ITALY: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 291 TABLE 406 ITALY: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 291 TABLE 407 ITALY: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 292 TABLE 408 ITALY: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 292 TABLE 409 ITALY: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 293 TABLE 410 ITALY: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 293 TABLE 411 ITALY: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 412 ITALY: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 294 TABLE 413 ITALY: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 294 TABLE 414 SPAIN: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 295 TABLE 415 SPAIN: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 296 TABLE 416 SPAIN: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 296 TABLE 417 SPAIN: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 296 TABLE 418 SPAIN: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 419 SPAIN: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 420 SPAIN: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 421 SPAIN: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 422 SPAIN: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 298 TABLE 423 SPAIN: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 299 TABLE 424 SPAIN: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 299 TABLE 425 SPAIN: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 300 TABLE 426 SPAIN: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 300 TABLE 427 SPAIN: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 300 TABLE 428 SPAIN: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 301 TABLE 429 REST OF EUROPE: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 302 TABLE 430 REST OF EUROPE: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 302 TABLE 431 REST OF EUROPE: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 432 REST OF EUROPE: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 433 REST OF EUROPE: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 434 REST OF EUROPE: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 435 REST OF EUROPE: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 436 REST OF EUROPE: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 437 REST OF EUROPE: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 305 TABLE 438 REST OF EUROPE: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 305 TABLE 439 REST OF EUROPE: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 306 TABLE 440 REST OF EUROPE: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 306 TABLE 441 REST OF EUROPE: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 306 TABLE 442 REST OF EUROPE: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 307 TABLE 443 REST OF EUROPE: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 307 TABLE 444 ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 309 TABLE 445 ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 309 TABLE 446 ASIA PACIFIC: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 310 TABLE 447 ASIA PACIFIC: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 310 TABLE 448 ASIA PACIFIC: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 310 TABLE 449 ASIA PACIFIC: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 311 TABLE 450 ASIA PACIFIC: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 311 TABLE 451 ASIA PACIFIC: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 311 TABLE 452 ASIA PACIFIC: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 312 TABLE 453 ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 312 TABLE 454 ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 313 TABLE 455 ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 313 TABLE 456 ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 314 TABLE 457 ASIA PACIFIC: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 314 TABLE 458 ASIA PACIFIC: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 314 TABLE 459 ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 315 TABLE 460 CHINA: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 316 TABLE 461 CHINA: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 316 TABLE 462 CHINA: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 317 TABLE 463 CHINA: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 317 TABLE 464 CHINA: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 317 TABLE 465 CHINA: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 318 TABLE 466 CHINA: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 318 TABLE 467 CHINA: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 318 TABLE 468 CHINA: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 319 TABLE 469 CHINA: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 319 TABLE 470 CHINA: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 320 TABLE 471 CHINA: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 320 TABLE 472 CHINA: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 320 TABLE 473 CHINA: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 321 TABLE 474 CHINA: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 321 TABLE 475 JAPAN: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 322 TABLE 476 JAPAN: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 323 TABLE 477 JAPAN: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 323 TABLE 478 JAPAN: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 323 TABLE 479 JAPAN: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 324 TABLE 480 JAPAN: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 324 TABLE 481 JAPAN: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 324 TABLE 482 JAPAN: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 325 TABLE 483 JAPAN: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 325 TABLE 484 JAPAN: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 326 TABLE 485 JAPAN: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 326 TABLE 486 JAPAN: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 327 TABLE 487 JAPAN: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 327 TABLE 488 JAPAN: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 327 TABLE 489 JAPAN: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 328 TABLE 490 INDIA: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 329 TABLE 491 INDIA: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 329 TABLE 492 INDIA: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 493 INDIA: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 494 INDIA: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 495 INDIA: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 331 TABLE 496 INDIA: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 331 TABLE 497 INDIA: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 331 TABLE 498 INDIA: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 332 TABLE 499 INDIA: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 332 TABLE 500 INDIA: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 333 TABLE 501 INDIA: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 333 TABLE 502 INDIA: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 333 TABLE 503 INDIA: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 334 TABLE 504 INDIA: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 334 TABLE 505 REST OF ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 335 TABLE 506 REST OF ASIA PACIFIC: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 336 TABLE 507 REST OF ASIA PACIFIC: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 336 TABLE 508 REST OF ASIA PACIFIC: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 336 TABLE 509 REST OF ASIA PACIFIC: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 337 TABLE 510 REST OF ASIA PACIFIC: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 337 TABLE 511 REST OF ASIA PACIFIC: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 337 TABLE 512 REST OF ASIA PACIFIC: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 338 TABLE 513 REST OF ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 338 TABLE 514 REST OF ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 339 TABLE 515 REST OF ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 339 TABLE 516 REST OF ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 340 TABLE 517 REST OF ASIA PACIFIC: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 340 TABLE 518 REST OF ASIA PACIFIC: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 340 TABLE 519 REST OF ASIA PACIFIC: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 341 TABLE 520 LATIN AMERICA: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 342 TABLE 521 LATIN AMERICA: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 342 TABLE 522 LATIN AMERICA: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 343 TABLE 523 LATIN AMERICA: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 343 TABLE 524 LATIN AMERICA: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 343 TABLE 525 LATIN AMERICA: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 344 TABLE 526 LATIN AMERICA: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 344 TABLE 527 LATIN AMERICA: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 344 TABLE 528 LATIN AMERICA: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 345 TABLE 529 LATIN AMERICA: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 345 TABLE 530 LATIN AMERICA: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 346 TABLE 531 LATIN AMERICA: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 346 TABLE 532 LATIN AMERICA: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 346 TABLE 533 LATIN AMERICA: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 347 TABLE 534 LATIN AMERICA: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 347 TABLE 535 MIDDLE EAST & AFRICA: IVD RAW MATERIALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 349 TABLE 536 MIDDLE EAST & AFRICA: ANTIBODIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 349 TABLE 537 MIDDLE EAST & AFRICA: ANTIGENS & PROTEINS MARKET, BY TYPE, 2024–2031 (USD MILLION) 350 TABLE 538 MIDDLE EAST & AFRICA: ENZYMES & SUBSTRATES MARKET, BY TYPE, 2024–2031 (USD MILLION) 350 TABLE 539 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDES & NUCLEIC ACIDS MARKET, BY TYPE, 2024–2031 (USD MILLION) 350 TABLE 540 MIDDLE EAST & AFRICA: BEADS & PARTICLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 351 TABLE 541 MIDDLE EAST & AFRICA: MEMBRANES MARKET, BY TYPE, 2024–2031 (USD MILLION) 351 TABLE 542 MIDDLE EAST & AFRICA: LABELS & DETECTION MATERIALS MARKET, BY TYPE, 2024–2031 (USD MILLION) 351 TABLE 543 MIDDLE EAST & AFRICA: IVD RAW MATERIALS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 352 TABLE 544 MIDDLE EAST & AFRICA: IVD RAW MATERIALS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 352 TABLE 545 MIDDLE EAST & AFRICA: IVD RAW MATERIALS MARKET, BY SUPPLY SOURCE, 2024–2031 (USD MILLION) 353 TABLE 546 MIDDLE EAST & AFRICA: IVD RAW MATERIALS MARKET, BY SOURCE/ORIGIN, 2024–2031 (USD MILLION) 353 TABLE 547 MIDDLE EAST & AFRICA: BIOLOGICAL/NATURAL SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 353 TABLE 548 MIDDLE EAST & AFRICA: RECOMBINANT/SYNTHETIC SOURCES MARKET, BY TYPE, 2024–2031 (USD MILLION) 354 TABLE 549 MIDDLE EAST & AFRICA: IVD RAW MATERIALS MARKET, BY END USER, 2024–2031 (USD MILLION) 354 TABLE 550 GLOBAL: NAT BASED PCR EQUIPMENT SOLD, 2024–2031 (THOUSAND UNITS) 355 TABLE 551 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN IVD RAW MATERIALS MARKET, JANUARY 2023−JULY 2026 356 TABLE 552 IVD RAW MATERIALS MARKET: DEGREE OF COMPETITION 359 TABLE 553 IVD RAW MATERIALS MARKET: REGION FOOTPRINT 362 TABLE 554 IVD RAW MATERIALS MARKET: PRODUCT TYPE FOOTPRINT 363 TABLE 555 IVD RAW MATERIALS MARKET: END-USER FOOTPRINT 364 TABLE 556 IVD RAW MATERIALS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 366 TABLE 557 IVD RAW MATERIALS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2) 366 TABLE 558 IVD RAW MATERIALS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2) 367 TABLE 559 IVD RAW MATERIALS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JULY 2026 370 TABLE 560 IVD RAW MATERIALS MARKET: DEALS, JANUARY 2023– JULY 2026 370 TABLE 561 MERCK KGAA: COMPANY OVERVIEW 372 TABLE 562 MERCK KGAA: PRODUCTS OFFERED 373 TABLE 563 MERCK KGAA: PRODUCT LAUNCHES & APPROVALS 380 TABLE 564 MERCK KGAA: DEALS 380 TABLE 565 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW 382 TABLE 566 THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED 383 TABLE 567 THERMO FISHER SCIENTIFIC INC.: PRODUCT ENHANCEMENTS 389 TABLE 568 THERMO FISHER SCIENTIFIC INC.: DEALS 389 TABLE 569 BIO-TECHNE CORPORATION: COMPANY OVERVIEW 391 TABLE 570 BIO-TECHNE CORPORATION: PRODUCTS & SERVICES OFFERED 392 TABLE 571 BIO-TECHNE CORPORATION: PRODUCT LAUNCHES & APPROVALS 399 TABLE 572 BIO-TECHNE CORPORATION: DEALS 399 TABLE 573 FAPON BIOTECH: COMPANY OVERVIEW 401 TABLE 574 FAPON BIOTECH: PRODUCTS & SERVICES OFFERED 402 TABLE 575 FAPON BIOTECH: PRODUCT LAUNCHES & APPROVALS 407 TABLE 576 MERIDIAN BIOSCIENCE: COMPANY OVERVIEW 408 TABLE 577 MERIDIAN BIOSCIENCE: PRODUCTS OFFERED 409 TABLE 578 MERIDIAN BIOSCIENCE: PRODUCT LAUNCHES 415 TABLE 579 MERIDIAN BIOSCIENCE: DEALS 415 TABLE 580 MEDIX BIOCHEMICA: COMPANY OVERVIEW 416 TABLE 581 MEDIX BIOCHEMICA: PRODUCTS & SERVICES OFFERED 417 TABLE 582 MEDIX BIOCHEMICA: DEALS 422 TABLE 583 MEDIX BIOCHEMICA: EXPANSIONS 423 TABLE 584 F. HOFFMANN-LA ROCHE: COMPANY OVERVIEW 424 TABLE 585 ROCHE CUSTOMBIOTECH: PRODUCTS & SERVICES OFFERED 425 TABLE 586 DANAHER CORPORATION: COMPANY OVERVIEW 431 TABLE 587 DANAHER CORPORATION: PRODUCTS OFFERED 432 TABLE 588 DANAHER CORPORATION: DEALS 440 TABLE 589 SARTORIUS AG: COMPANY OVERVIEW 441 TABLE 590 SARTORIUS AG: PRODUCTS OFFERED 442 TABLE 591 HYTEST LTD.: COMPANY OVERVIEW 445 TABLE 592 HYTEST LTD.: PRODUCTS OFFERED 445 TABLE 593 TOYOBO CO., LTD.: COMPANY OVERVIEW 453 TABLE 594 TOYOBO CO., LTD.: PRODUCTS OFFERED 454 TABLE 595 LGC BIOSEARCH TECHNOLOGIES: COMPANY OVERVIEW 460 TABLE 596 LGC BIOSEARCH TECHNOLOGIES: PRODUCTS OFFERED 461 TABLE 597 BBI SOLUTIONS: COMPANY OVERVIEW 466 TABLE 598 SURMODICS IVD: COMPANY OVERVIEW 467 TABLE 599 AHLSTROM OYJ: COMPANY OVERVIEW 468 TABLE 600 BANGS LABORATORIES: COMPANY OVERVIEW 469 TABLE 601 SCRIPPS LABORATORIES, INC.: COMPANY OVERVIEW 470 TABLE 602 MIKROGEN GMBH: COMPANY OVERVIEW 471 TABLE 603 ADVANCED MICRODEVICES PVT. LTD.: COMPANY OVERVIEW 472 TABLE 604 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW 473 TABLE 605 RANDOX LABORATORIES LTD.: COMPANY OVERVIEW 474 TABLE 606 HIMEDIA LABORATORIES: COMPANY OVERVIEW 475 TABLE 607 SINO BIOLOGICAL: COMPANY OVERVIEW 476 TABLE 608 BIOSYNTH: COMPANY OVERVIEW 477 TABLE 609 NEW ENGLAND BIOLABS, INC.: COMPANY OVERVIEW 478 FIGURE 1 IVD RAW MATERIALS MARKET SEGMENTATION 42 FIGURE 2 REGIONAL SCOPE 43 FIGURE 3 KEY INSIGHTS AND MARKET HIGHLIGHTS 45 FIGURE 4 GLOBAL IVD RAW MATERIALS MARKET, 2024–2031 45 FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN IVD RAW MATERIALS MARKET, 2023–2026 46 FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF IVD RAW MATERIALS MARKET 47 FIGURE 7 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN IVD RAW MATERIALS MARKET, 2025 48 FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 49 FIGURE 9 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET 50 FIGURE 10 ANTIBODIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 51 FIGURE 11 IMMUNOASSAY SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 51 FIGURE 12 INFECTIOUS DISEASES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 52 FIGURE 13 IN-HOUSE MANUFACTURING SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 52 FIGURE 14 BIOLOGICAL/NATURAL SOURCES TO LEAD MARKET DURING FORECAST PERIOD 53 FIGURE 15 IVD MANUFACTURERS SEGMENT TO COMMAND LARGEST SHARE DURING FORECAST PERIOD 53 FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 54 FIGURE 17 IVD RAW MATERIALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 55 FIGURE 18 IVD RAW MATERIALS MARKET: PORTER’S FIVE FORCES ANALYSIS 68 FIGURE 19 IVD RAW MATERIALS MARKET: SUPPLY CHAIN ANALYSIS 73 FIGURE 20 IVD RAW MATERIALS MARKET: VALUE CHAIN ANALYSIS 74 FIGURE 21 IVD RAW MATERIALS MARKET: ECOSYSTEM ANALYSIS 75 FIGURE 22 IVD RAW MATERIALS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS 80 FIGURE 23 DEALS & FUNDING ACTIVITIES IN IVD RAW MATERIALS MARKET 80 FIGURE 24 PATENT ANALYSIS FOR IVD RAW MATERIALS, JANUARY 2016–DECEMBER 2025 87 FIGURE 25 MARKET POTENTIAL OF AI IN IVD RAW MATERIALS MARKET 90 FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 101 FIGURE 27 KEY BUYING CRITERIA, BY END USER 102 FIGURE 28 NORTH AMERICA: IVD RAW MATERIALS MARKET SNAPSHOT 240 FIGURE 29 ASIA PACIFIC: IVD RAW MATERIALS MARKET SNAPSHOT 308 FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS IN IVD RAW MATERIALS MARKET, 2023–2025 (USD MILLION) 358 FIGURE 31 IVD RAW MATERIALS MARKET SHARE ANALYSIS, 2025 (GLOBAL) 358 FIGURE 32 IVD RAW MATERIALS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 361 FIGURE 33 IVD RAW MATERIALS MARKET: COMPANY FOOTPRINT 362 FIGURE 34 IVD RAW MATERIALS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 365 FIGURE 35 EV/EBITDA OF KEY VENDORS 367 FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 368 FIGURE 37 IVD RAW MATERIALS MARKET: BRAND/PRODUCT COMPARISON FOR RECOMBINANT HUMAN IL-6 PROTEIN 369 FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2025) 373 FIGURE 39 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2025) 383 FIGURE 40 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2025) 392 FIGURE 41 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2025) 425 FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 432 FIGURE 43 SARTORIUS AG: COMPANY SNAPSHOT (2025) 442 FIGURE 44 TOYOBO CO., LTD.: COMPANY SNAPSHOT (2025) 454 FIGURE 45 LGC BIOSEARCH TECHNOLOGIES: COMPANY SNAPSHOT (2025) 461 FIGURE 46 RESEARCH DESIGN 479 FIGURE 47 KEY DATA FROM SECONDARY SOURCES 481 FIGURE 48 LIST OF PRIMARY SOURCES 482 FIGURE 49 KEY INDUSTRY INSIGHTS 483 FIGURE 50 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 484 FIGURE 51 APPROACH 1: REVENUE ESTIMATION OF KEY PLAYERS 485 FIGURE 52 CAGR PROJECTIONS 486 FIGURE 53 TOP-DOWN APPROACH 487 FIGURE 54 DATA TRIANGULATION 488 FIGURE 55 PARAMETRIC ASSUMPTIONS 489

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們